Advanced in Large-Cell Immunoblastic Lymphoma

Lara H. Bohmer

Haag, LI, NL 
Advanced in Large-Cell Immunoblastic Lymphoma
Haag, LI, NL 
OverviewLocationsClinical Research

Overview

Lara Bohmer practices in Haag, Netherlands. Ms. Bohmer is rated as an Advanced expert by MediFind in the treatment of Large-Cell Immunoblastic Lymphoma. Her top areas of expertise are Diffuse Large B-Cell Lymphoma (DLBCL), Peripheral T-Cell Lymphoma, Non-Hodgkin Lymphoma, and B-Cell Lymphoma.

Her clinical research consists of co-authoring 22 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Large-Cell Immunoblastic Lymphoma.

Gender
Female

Locations

Haag, LI, Netherlands
Other Locations
The Hague, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Enrollment Status: Active_not_recruiting
Publish Date: May 28, 2025
Intervention Type: Drug
Study Drugs: LOXO-305, Ibrutinib, Acalabrutinib, Zanubrutinib
Study Phase: Phase 3
Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma
Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma
Enrollment Status: Completed
Publish Date: March 05, 2025
Intervention Type: Drug
Study Drugs: R-CHOP, R-CHOP/R-HAD, Rituximab, Lenalidomide
Study Phase: Phase 3
View 1 Less Clinical Trial

22 Total Publications

Influence of Survivorship Care on Health-Related Quality of Life, Knowledge of Late Effects, and Distress Levels Among Long-Term Hodgkin Lymphoma Survivors.
Influence of Survivorship Care on Health-Related Quality of Life, Knowledge of Late Effects, and Distress Levels Among Long-Term Hodgkin Lymphoma Survivors.
Journal: Cancer medicine
Published: February 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Bohmer's expertise for a condition
ConditionClose
    View All 9 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile